Abstract Details

Title A Retrospective Cohort Study of Medical Cannabis Treatment in Patients with Glioblastoma Multiforme

Topic Neuro-oncology

Presentation(s) Neuro-oncology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 004

Objective To evaluate the effect of medical cannabis (MC) on survival rates, quality of life, and adverse effects in patients with pathology-confirmed glioblastoma multiforme.

Background MC is becoming increasingly available to patients battling cancer, but additional evidence is required for proper treatment plan formulation. This retrospective cohort chart review investigated the role of MC in patients with glioblastoma multiforme, a rare, terminal, and aggressive malignancy.

Design/Methods Between March 2016 to October 2019, 48 patients with pathology-confirmed glioblastoma multiforme utilized New York State MC. Survival and quality of life outcomes were compared to a matched control group, including pathology grading and tumor genotype, who were not exposed to MC. All patients were followed in an outpatient neuro-oncology setting in New York State.

Results No significance was observed in the median survival time between patients with glioblastoma multiforme utilizing MC (24.7 months) and matched controls (22.4 months, p=0.862). Five year survival rates supported these findings (MC: 28.6%, control: 31.6%). Average MC exposure was 9.34±8.50 months in 48 patients (median age 51 years, 58% female, 30% reporting previous cannabis use). Patient-reported improvements were most notable in sleep (70%), overall quality of life (65%), and anxiety (52%). Adverse effects of MC were reported in 26% and were mostly mild in nature. The utilization of Type II chemovar (balanced tetrahydrocannabinol to cannabidiol ratio) was associated with increased quality of life measures, including improved sleep and anxiety, while minimizing AE reporting.

Conclusions There is no association between improved survival of glioblastoma multiforme and MC treatment. MC may be considered as complementary therapy for the improvement of QOL measures that may be effected during the course of standard glioblastoma multiforme care, including sleep and anxiety. Randomized, placebo-controlled studies are required to further investigate these associations, with an emphasis on improving patient quality of life and survival outcomes for glioblastoma multiforme.

Authors/Disclosures
Vincent H. Bargnes III PRESENTER	Mr. Bargnes has received research support from Harry Dent Family Foundation.
Laszlo Mechtler, MD, FEAN, FASN, FAHS, FAAN (Dent Neurologic Institute)	Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharma. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Genomate Health. The institution of Dr. Mechtler has received research support from The Harry Dent Family Foundation, Inc. The institution of Dr. Mechtler has received research support from Alpheus medical. The institution of Dr. Mechtler has received research support from Shiratronics. The institution of Dr. Mechtler has received research support from Abbvie Inc. The institution of Dr. Mechtler has received research support from Amgen. The institution of Dr. Mechtler has received research support from Eli Lilly Company. The institution of Dr. Mechtler has received research support from H. Lundbeck HS. The institution of Dr. Mechtler has received research support from Pfizer. Dr. Mechtler has received personal compensation in the range of $100,000-$499,999 for serving as a Ownership interest with Neurology Practce Consortium GPO. Dr. Mechtler has a non-compensated relationship as a Board member with International Headache Society that is relevant to AAN interests or activities.
	No disclosure on file
Paul B. Hart	Mr. Hart has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��